<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948180</url>
  </required_header>
  <id_info>
    <org_study_id>CM-2013-01</org_study_id>
    <nct_id>NCT01948180</nct_id>
  </id_info>
  <brief_title>Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma</brief_title>
  <acronym>CITADEL</acronym>
  <official_title>A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Medica Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cell Medica Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients&#xD;
      with aggressive EBV positive extranodal NK/T-cell lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment rate&#xD;
  </why_stopped>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">September 7, 2018</completion_date>
  <primary_completion_date type="Actual">April 16, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as best observed response (complete response or partial response) per Lugano 2014 Disease Response Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunological assessment of EBV-specific T-cell activity and phenotyping</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Monitor levels of plasma and whole blood EBV DNA (viral load)</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Lymphoma, Extranodal NK-T-Cell</condition>
  <condition>EBV</condition>
  <arm_group>
    <arm_group_label>baltaleucel-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.&#xD;
Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>baltaleucel-T</intervention_name>
    <description>Autologous EBV-specific T-cells</description>
    <arm_group_label>baltaleucel-T</arm_group_label>
    <other_name>CMD-003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        FOR SCREENING PHASE:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of extranodal NK/T lymphoma, per WHO classification, 4th ed., which must&#xD;
             include EBV tumor positivity, measured either by EBV encoded RNA (EBER) or LMP1&#xD;
             immunostaining.&#xD;
&#xD;
          2. a) Active Disease&#xD;
&#xD;
        (1) Clinically suspected or documented relapse/progression, in first or second relapse&#xD;
        following at least one cycle of an asparaginase-based chemotherapy regimen OR (2) Initial&#xD;
        disease or first or second relapse and unable to tolerate one full cycle of&#xD;
        asparaginase-based chemotherapy regimen OR b) High-risk disease (stage III/IV, KPI groups&#xD;
        3-4 or IPI intermediate-high) prior to second CR regardless of previous chemotherapy.&#xD;
&#xD;
        3. Male or female ≥ 18 years of age. 4. Weigh ≥ 35 kg. 5. ECOG performance score 0-2,&#xD;
        inclusively. 6. Negative β-hCG test in women of childbearing potential. 7. Able to&#xD;
        understand and comply with the requirements of the study and to provide written informed&#xD;
        consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CNS lymphoma.&#xD;
&#xD;
          2. NK cell leukemia.&#xD;
&#xD;
          3. Hemophagocytic lymphohistiocytosis.&#xD;
&#xD;
          4. Positive for HIV, hepatitis B, hepatitis C, syphilis or human T Cell leukemia virus&#xD;
             (HTLV).&#xD;
&#xD;
          5. Use of systemic corticosteroids &gt;0.5 mg/kg/day within 10 days prior to obtaining 200&#xD;
             mL whole blood starting material.&#xD;
&#xD;
          6. Patient is pregnant or lactating.&#xD;
&#xD;
          7. Active second malignancy.&#xD;
&#xD;
          8. Any prior allogeneic hematopoietic stem cell or solid organ transplant.&#xD;
&#xD;
          9. Asparaginase refractory disease, defined by any one of the following:&#xD;
&#xD;
               1. Progression at any time during initial asparaginase based chemotherapy and up to&#xD;
                  3 months after end of initial asparaginase based chemotherapy, OR&#xD;
&#xD;
               2. Failure to achieve at least PR with initial asparaginase based chemotherapy.&#xD;
&#xD;
         10. Absolute lymphocyte count (ALC) &lt;400/µL.&#xD;
&#xD;
         11. Any previous autologous EBV specific T cell treatment.&#xD;
&#xD;
         12. Systemic fungal, bacterial, viral or other infection that is not controlled.&#xD;
&#xD;
         13. Third or greater relapse.&#xD;
&#xD;
        FOR TREATMENT PHASE:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented relapse or progression following at least one prior cycle of an&#xD;
             asparaginase-containing chemotherapy regimen.&#xD;
&#xD;
          2. Active disease based on any one of the following present at the baseline study visit&#xD;
             or within two weeks prior to the baseline study visit:&#xD;
&#xD;
               1. Imaging (may use local imaging)&#xD;
&#xD;
               2. Clinical sign(s) including skin lesions consistent with lymphoma, organ&#xD;
                  dysfunction or organomegaly not attributable to other causes; or other clinical&#xD;
                  sign(s)&#xD;
&#xD;
               3. Detectable blood or plasma ENV DNA (may use local laboratory)&#xD;
&#xD;
          3. Completed most recent course of chemotherapy at least 2 weeks prior to first study&#xD;
             drug dose.&#xD;
&#xD;
          4. Recovery from acute hematological, hepatic and renal chemotherapy-related toxicities&#xD;
             as defined by ≤ Grade 1 according to NCI CTCAE v4.0.&#xD;
&#xD;
          5. Life expectancy ≥ 8 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any investigational agents within prior 4 weeks.&#xD;
&#xD;
          2. Radiotherapy within prior 3 weeks.&#xD;
&#xD;
          3. Major surgery within prior 2 weeks.&#xD;
&#xD;
          4. Systemic corticosteroids within 24 hours prior to study drug administration.&#xD;
&#xD;
          5. Evidence of hepatic dysfunction based on serum total bilirubin &gt;3 times upper limit of&#xD;
             normal (ULN), or ALT &gt;5 times ULN or AST &gt;5 times ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Heslop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Gunter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cell Medica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ouest</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lyon</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Cancer Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie Clinic</name>
      <address>
        <city>Manchester</city>
        <state>UK</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 13, 2013</study_first_submitted>
  <study_first_submitted_qc>September 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2013</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NKTCL</keyword>
  <keyword>T cell</keyword>
  <keyword>CITADEL</keyword>
  <keyword>Epstein-Barr Virus</keyword>
  <keyword>Natural Killer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 9, 2019</submitted>
    <returned>August 2, 2019</returned>
    <submitted>September 26, 2019</submitted>
    <returned>October 17, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

